药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Temsirolimus
The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Temsirolimus.
Tiludronic acid
Tariquidar
The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tariquidar.
Tiludronic acid
Zosuquidar
The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Zosuquidar.
Tiludronic acid
Prednisolone phosphate
The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Prednisolone phosphate.
Tiludronic acid
Etravirine
The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Etravirine.
Tiludronic acid
Odesivimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Odesivimab.
Tiludronic acid
Maftivimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Maftivimab.
Tiludronic acid
Atoltivimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atoltivimab.
Tiludronic acid
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Trastuzumab deruxtecan.
Tiludronic acid
Zenocutuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Zenocutuzumab.
Tiludronic acid
Naratuximab emtansine
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Naratuximab emtansine.
Tiludronic acid
Lorukafusp alfa
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lorukafusp alfa.
Tiludronic acid
Lulizumab pegol
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lulizumab pegol.
Tiludronic acid
Pinatuzumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pinatuzumab vedotin.
Tiludronic acid
Vesencumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vesencumab.
Tiludronic acid
Tomaralimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tomaralimab.
Tiludronic acid
Ladiratuzumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ladiratuzumab vedotin.
Tiludronic acid
GMA-161
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with GMA-161.
Tiludronic acid
Pidilizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pidilizumab.
Tiludronic acid
Istiratumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Istiratumab.